Gilead's China Remdesivir Patents Confirmed, Generics Firms Cautioned
US Firm Gains Upper Hand Amid Patent Dispute
As the front-runner antiviral in the fight against the coronavirus gets increasingly positive attention in China, officials take action to keep the originator front and center and domestic copycats at bay.
You may also be interested in...
Hetero is one of the new licensees for Gilead’s remdesivir, the investigational antiviral in the spotlight as a potential treatment for COVID-19, and the Indian group’s managing director shares insights on its supply chain readiness and the royalty model of the deal.
Public health officials in Massachusetts say Biogen company meeting is source of 70 cases in the state.
Already priced domestically at a deep discount to counterpart PD-1s in the US, Beigene's tislelizumab could potentially get the first global approval for a China-originated drug in this class, as the immuno-oncology sector as a whole continues to come under pressure in China.